Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
在首次复发/难治性急性淋巴细胞白血病患者中,与blinatumomab相比,inotuzumab ozogamicin在实际应用中可降低医疗保健成本。
期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2023-0142
Russell-Smith, Alexander; Murphy, Louise; Nguyen, Amy; Blauer-Peterson, Cori; Terpenning, Marilou; Cao, Feng; Li, Shiqiang; Bancroft, Tim; Webb, Noah; Dorman, Stephanie; Shah, Richa